Neochem Bio Solutions Ltd Mar 2026: Working Capital Exploded to 164 Days as Cash Flow Evaporates

Section 1 — At a Glance

Neochem Bio Solutions Limited’s full-year fiscal 2026 performance presents a glaring divergence between accounting profitability and cash reality. Top-line revenue surged 31.51% to ₹110.70 crore compared to ₹84.17 crore in the previous fiscal year. This revenue growth was mirrored by an expansion in net profit, which jumped 61.69% to ₹12.03 crore, up from ₹7.44 crore in fiscal 2025. Profit margins expanded alongside this scaling, with the operational profit margin climbing to 17.9% and the net profit margin touching 10.6%. Investors are heavily drawn to the company’s aggressive business diversification into the home and personal care ingredient sector, alongside its structural debt reduction following its SME IPO listing in December 2025.

However, beneath this veneer of rapid growth lies an alarming operational bottleneck that is rapidly draining corporate liquidity. The company’s working capital cycle has expanded to 164 days from 38 days in the prior year, driven primarily by a surge in debtor days from 108 to 161 days. This aggressive credit extension has frozen liquid cash, causing cash flow from operating activities to collapse from a positive ₹2.20 crore to a negative ₹19.06 crore. Profit that only exists on an invoice cannot fund factory operations or reward shareholders. The market is tracking whether this asset-light scaling can sustain itself without triggering a persistent liquidity crunch.

Section 2 — Introduction

Neochem Bio Solutions Limited, established originally in 2006 as a partnership before converting into a public corporate entity, has repositioned its operating identity to ride the structural tailwinds of specialized industrial chemistry. The firm concluded its corporate milestone by raising ₹42.70 crore through an SME initial public offering on the National Stock Exchange in December 2025. The capital infusion was earmarked to alter its balance sheet profile through debt retirement and to inject raw liquid capital into its expanding working capital requirements. This article analyzes the audited financial statement architecture for the full year ending March 2026, evaluating whether the capital market listing has structurally fortified the business or merely masked intensifying operational inefficiencies.

Section 3 — Business Model: WTF Do They Even Do?

Neochem manufactures customized performance chemical formulations, maintaining a library of over 350 specialized recipes across four categories: polymers, surfactants, silicones, and bio-based esters. Historically, the business has operated as a dedicated auxiliary provider to the textile processing industry, which still commands 77% of its aggregate revenue mix.

Revenue by Application (6MFY26):
├── Textile: 77%
├── Home & Personal Care (HPCI): 14.2%
└── Paint, Coatings & Dyes: 9%

The manufacturing process runs via batch production at a single 22,000 MTPA facility in Moraiya, Ahmedabad, which reached a capacity utilization of 52.7% in fiscal 2026. To mitigate customer concentration risks—where the top ten buyers swallow 55% of total volumes—management is attempting to seed products into the home and personal care, water treatment, and coatings sectors.

Is it an easy business? Far from it. It requires high domestic high-touch service via 50+ distributors to keep 227 clients happy.

Section 4 — Financials Overview

Figures are standalone, in ₹ crore.

Full-Year Performance Comparison

The full-year audited data indicates that raw material costs grew in lockstep with the top line, tracking at ₹73.57 crore. Operational efficiency gains became visible at the EBITDA line, which grew to ₹21.94 crore, representing a 19.82% margin due to lower comparative selling and administrative outlays. The contraction in individual reported Earnings Per Share (EPS) from ₹11.15 to ₹7.03 is not an operational failure; it is the mathematical result of equity dilution following a massive expansion of the